Abstract: Objective To observe the efficacy and safety of nedaplatin combined with gemcitabine for advanced multipletreatment after failure of squamous cell lung cancer.
MethodsTwentysix advanced multipletreatment patients were enrolled in this study with histologically or cytologically diagnosed as squamous cell carcinoma， which were given nedaplatin 80mg／m2 d1， gemcitabine 1000mg／m2， d1 and d8. Twentyone days was a cycle. Efficacy and toxicity were evaluated after 12 cycles， and progressionfree survival（PFS） was observed.
ResultsTwentythree patients were available for efficacy， with no complete remission cases， 6 cases of partial remission， 12 cases of stable and 5 cases of progress. Total response rate was 261％， the clinical benefit rate was 783％. The median PFS was 4 months. Major toxicities were liver damage and gastrointestinal tract， myelosuppression was obvious but can be tolerated.
ConclusionNedaplatin combined with gemcitabine in advanced multipletreatment after failure of squamous cell lung cancer is efficacy. The toxicity can be tolerated， worthy of further dissemination and research.